We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care
Read MoreHide Full Article
Key Takeaways
Smith Nephew launched the EVOS PELVIC System for complex pelvic and acetabular fracture management.
SNN's new system combines dedicated plates, cannulated screws and instruments to support surgical efficiency.
Smith Nephew expands EVOS into a pelvic trauma market projected to reach $4.79 billion by 2034.
Smith+Nephew (SNN - Free Report) recently launched the new EVOS PELVIC Plating System, expanding its EVOS trauma platform into pelvic and acetabular fracture management. The launch strengthens the company’s orthopedic trauma portfolio by adding a dedicated solution for complex procedures.
The launch could support Smith+Nephew’s long-term growth by broadening its addressable market within trauma care and creating opportunities to deepen relationships with orthopedic surgeons and hospitals. The new offering also highlights the company’s focus on procedural innovation, which could help drive adoption and strengthen its competitive position in the orthopedic market.
Likely Trend of SNN Stock Following the News
Following the announcement on Sept. 23, shares of SNN traded flat in yesterday’s market. Year to date, shares of the company have lost 17.6% compared with the industry’s 21.6% decline. However, the S&P 500 has risen 11.7% in the same timeframe.
The launch of the EVOS PELVIC Plating System is likely to benefit SNN’s long-term business by expanding its presence in the pelvic and acetabular trauma market and broadening the reach of its EVOS platform. The addition of a dedicated solution could support portfolio-driven sales growth as the company gains opportunities to serve more complex fracture procedures and strengthen relationships with trauma surgeons and healthcare providers. Over time, broader adoption of the EVOS PELVIC System could also improve the platform’s revenue contribution while reinforcing Smith+Nephew’s focus on differentiated orthopedic trauma solutions.
SNN currently has a market capitalization of $11.37 billion.
Image Source: Zacks Investment Research
EVOS PELVIC System Expands Trauma Portfolio
The EVOS PELVIC Plating System is designed to address a broad range of pelvic and acetabular fracture patterns, with an emphasis on simplifying technically demanding procedures. The system incorporates dedicated plates and instrumentation that are designed to work together during plate-assisted reduction.
Smith+Nephew said that the platform includes pre-contoured options for the posterior wall, quadrilateral surface and pubic symphysis, along with locking and non-locking utility plates. This broader implant offering is intended to provide surgeons with greater flexibility when managing complex pelvic ring and acetabular fractures across different patient populations.
Integrated Design Supports Surgical Efficiency
A key feature of the new system is its dedicated cannulated screw platform and specialized instruments designed to support fracture exposure, reduction and implant placement. According to Smith+Nephew, the integrated design allows surgeons to obtain and fine-tune fracture reduction using features incorporated into the plates and instruments before maintaining fixation through the healing process.
The company believes this approach could make complex pelvic procedures more efficient and reproducible. The EVOS PELVIC System is currently available in the United States, while the timing and availability in other markets will vary.
Industry Prospects Favoring the Market
Going by the data provided by Data Insights Reports, the global pelvic trauma management market was valued at $2.81 billion in 2025 and is projected to reach $4.79 billion by 2034, expanding at a 6.1% CAGR.
Growth is supported by an increase in high-energy pelvic fractures from road traffic accidents, falls in the aging population and wider adoption of surgical fixation protocols.
Other News
In August, SNN announced the launch of the FLOW FLEXTEND COBLATION Wand, a new RF resection technology designed to improve joint access and tissue targeting during complex hip procedures. The wand extends the company’s proprietary FLOW~IQ technology with an adjustable-angle tip, enabling surgeons to reach hard-to-access hip, knee and shoulder anatomies while supporting precise and efficient tissue removal.
Globus Medical, currently carrying a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care
Key Takeaways
Smith+Nephew (SNN - Free Report) recently launched the new EVOS PELVIC Plating System, expanding its EVOS trauma platform into pelvic and acetabular fracture management. The launch strengthens the company’s orthopedic trauma portfolio by adding a dedicated solution for complex procedures.
The launch could support Smith+Nephew’s long-term growth by broadening its addressable market within trauma care and creating opportunities to deepen relationships with orthopedic surgeons and hospitals. The new offering also highlights the company’s focus on procedural innovation, which could help drive adoption and strengthen its competitive position in the orthopedic market.
Likely Trend of SNN Stock Following the News
Following the announcement on Sept. 23, shares of SNN traded flat in yesterday’s market. Year to date, shares of the company have lost 17.6% compared with the industry’s 21.6% decline. However, the S&P 500 has risen 11.7% in the same timeframe.
The launch of the EVOS PELVIC Plating System is likely to benefit SNN’s long-term business by expanding its presence in the pelvic and acetabular trauma market and broadening the reach of its EVOS platform. The addition of a dedicated solution could support portfolio-driven sales growth as the company gains opportunities to serve more complex fracture procedures and strengthen relationships with trauma surgeons and healthcare providers. Over time, broader adoption of the EVOS PELVIC System could also improve the platform’s revenue contribution while reinforcing Smith+Nephew’s focus on differentiated orthopedic trauma solutions.
SNN currently has a market capitalization of $11.37 billion.
Image Source: Zacks Investment Research
EVOS PELVIC System Expands Trauma Portfolio
The EVOS PELVIC Plating System is designed to address a broad range of pelvic and acetabular fracture patterns, with an emphasis on simplifying technically demanding procedures. The system incorporates dedicated plates and instrumentation that are designed to work together during plate-assisted reduction.
Smith+Nephew said that the platform includes pre-contoured options for the posterior wall, quadrilateral surface and pubic symphysis, along with locking and non-locking utility plates. This broader implant offering is intended to provide surgeons with greater flexibility when managing complex pelvic ring and acetabular fractures across different patient populations.
Integrated Design Supports Surgical Efficiency
A key feature of the new system is its dedicated cannulated screw platform and specialized instruments designed to support fracture exposure, reduction and implant placement. According to Smith+Nephew, the integrated design allows surgeons to obtain and fine-tune fracture reduction using features incorporated into the plates and instruments before maintaining fixation through the healing process.
The company believes this approach could make complex pelvic procedures more efficient and reproducible. The EVOS PELVIC System is currently available in the United States, while the timing and availability in other markets will vary.
Industry Prospects Favoring the Market
Going by the data provided by Data Insights Reports, the global pelvic trauma management market was valued at $2.81 billion in 2025 and is projected to reach $4.79 billion by 2034, expanding at a 6.1% CAGR.
Growth is supported by an increase in high-energy pelvic fractures from road traffic accidents, falls in the aging population and wider adoption of surgical fixation protocols.
Other News
In August, SNN announced the launch of the FLOW FLEXTEND COBLATION Wand, a new RF resection technology designed to improve joint access and tissue targeting during complex hip procedures. The wand extends the company’s proprietary FLOW~IQ technology with an adjustable-angle tip, enabling surgeons to reach hard-to-access hip, knee and shoulder anatomies while supporting precise and efficient tissue removal.
SNN’s Zacks Rank & Key Picks
Currently, SNN has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.